Rifaximin for preventing episodes of overt hepatic encephalopathy

Rifaximin for the maintenance treatment of hepatic encephalopathy [ID496]: equality impact assessment - guidance development (PDF 177 KB)

Final appraisal determination information

Final appraisal determination document (PDF 307 KB)

Committee papers information

Committee papers (PDF 4.33 MB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: appraisal consultation 2

Hepatic encephalopathy (maintenance treatment) - rifaximin: appraisal consultation 2 document information

Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report 2 information

Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report 2 (PDF 3.38 MB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: appraisal consultation

Hepatic encephalopathy (maintenance treatment) - rifaximin: appraisal consultation document information

Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report information

Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report (PDF 5.77 MB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: final matrix (PDF 39 KB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: final scope (PDF 98 KB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: response to consultee and commentator comments on the draft scope and provisional matrix (PDF 368 KB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: equality impact assessment - scoping (PDF 64 KB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: draft scope for consultation (PDF 74 KB)

Hepatic encephalopathy (maintenance treatment) - rifaximin: provisional matrix (PDF 73 KB)

Appendix B - draft scope for consultation (pre-referral) - May 2011 (superseded) (PDF 53 KB)

Appendix C - provisional matrix (pre-referral) - May 2011 (superseded) (PDF 32 KB)